Iterum Therapeutics (ITRM) Competitors $1.63 +0.11 (+7.24%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ITRM vs. NBRV, SPRO, TTPH, ETTX, PRTK, INZY, NBTX, KYTX, CRBU, and SCPHShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Nabriva Therapeutics (NBRV), Spero Therapeutics (SPRO), Tetraphase Pharmaceuticals (TTPH), Entasis Therapeutics (ETTX), Paratek Pharmaceuticals (PRTK), Inozyme Pharma (INZY), Nanobiotix (NBTX), Kyverna Therapeutics (KYTX), Caribou Biosciences (CRBU), and scPharmaceuticals (SCPH). These companies are all part of the "medical" sector. Iterum Therapeutics vs. Nabriva Therapeutics Spero Therapeutics Tetraphase Pharmaceuticals Entasis Therapeutics Paratek Pharmaceuticals Inozyme Pharma Nanobiotix Kyverna Therapeutics Caribou Biosciences scPharmaceuticals Iterum Therapeutics (NASDAQ:ITRM) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Does the MarketBeat Community favor ITRM or NBRV? Nabriva Therapeutics received 252 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. However, 62.95% of users gave Iterum Therapeutics an outperform vote while only 56.22% of users gave Nabriva Therapeutics an outperform vote. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Nabriva TherapeuticsOutperform Votes39356.22% Underperform Votes30643.78% Which has more risk and volatility, ITRM or NBRV? Iterum Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Is ITRM or NBRV more profitable? Iterum Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Iterum Therapeutics' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -152.62% Nabriva Therapeutics -148.11%-365.53%-135.81% Do analysts recommend ITRM or NBRV? Iterum Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 206.75%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Iterum Therapeutics is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, ITRM or NBRV? Iterum Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$38.37M-$2.00-0.82Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Do institutionals & insiders have more ownership in ITRM or NBRV? 9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 9.2% of Iterum Therapeutics shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor ITRM or NBRV? In the previous week, Iterum Therapeutics had 5 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 6 mentions for Iterum Therapeutics and 1 mentions for Nabriva Therapeutics. Iterum Therapeutics' average media sentiment score of 0.21 beat Nabriva Therapeutics' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iterum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nabriva Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIterum Therapeutics beats Nabriva Therapeutics on 13 of the 17 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.85M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-0.8210.57134.3717.77Price / SalesN/A243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book-3.405.474.674.68Net Income-$38.37M$153.61M$119.07M$226.08M7 Day Performance19.85%-2.00%-1.83%-1.04%1 Month Performance45.54%-7.47%-3.62%1.04%1 Year Performance-4.68%31.80%31.63%26.28% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.0468 of 5 stars$1.63+7.2%$5.00+206.7%+18.1%$44.85MN/A-0.8210NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M-0.0739Analyst ForecastNews CoverageSPROSpero Therapeutics4.5933 of 5 stars$1.20+3.4%$5.00+316.7%-2.4%$63.24M$103.78M17.1546Analyst ForecastTTPHTetraphase PharmaceuticalsN/A$2.20flatN/A+0.0%$15.98M$7.38M-0.10119ETTXEntasis TherapeuticsN/A$2.19flatN/A+0.0%$104.80M$7M-1.9651PRTKParatek Pharmaceuticals0.0194 of 5 stars$2.23+1.8%N/A+0.0%$127.82M$160.27M-2.03268High Trading VolumeINZYInozyme Pharma1.2302 of 5 stars$2.79-0.7%$15.71+463.2%-28.5%$179.23MN/A-1.7950NBTXNanobiotix2.3367 of 5 stars$4.07+7.7%$11.50+182.7%-33.5%$178.16M$39.18M0.00100Positive NewsKYTXKyverna Therapeutics2.4324 of 5 stars$4.12+1.0%$25.71+524.1%N/A$177.86M$7.03M0.0096Analyst ForecastAnalyst RevisionGap UpCRBUCaribou Biosciences2.9283 of 5 stars$1.96-1.5%$11.25+474.0%-64.7%$177.48M$11.48M-1.19100SCPHscPharmaceuticals3.8122 of 5 stars$3.36-4.5%$15.00+346.4%-40.2%$176.14M$13.59M0.0030Analyst Revision Related Companies and Tools Related Companies Nabriva Therapeutics Alternatives Spero Therapeutics Alternatives Tetraphase Pharmaceuticals Alternatives Entasis Therapeutics Alternatives Paratek Pharmaceuticals Alternatives Inozyme Pharma Alternatives Nanobiotix Alternatives Kyverna Therapeutics Alternatives Caribou Biosciences Alternatives scPharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ITRM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITRM Stock Alerts